PT2385 selectively binds HIF-2α (Kd < 50 nM)—but not HIF-1α—to prevent it from binding to HIF-1β and has shown promise in preclinical studies (22) and clinical trials on patients with renal cell carcinoma (23, 24). This evidence concerns the gene HIF1A and hereditary clear cell renal cell carcinoma.